BR9809147A - Substituted pyrazole compound, pharmaceutical composition, processes for treating a tnf mediated disorder, a p38 kinase mediated disorder, inflammation and arthritis, and for preparing pyrazoles - Google Patents

Substituted pyrazole compound, pharmaceutical composition, processes for treating a tnf mediated disorder, a p38 kinase mediated disorder, inflammation and arthritis, and for preparing pyrazoles

Info

Publication number
BR9809147A
BR9809147A BR9809147-6A BR9809147A BR9809147A BR 9809147 A BR9809147 A BR 9809147A BR 9809147 A BR9809147 A BR 9809147A BR 9809147 A BR9809147 A BR 9809147A
Authority
BR
Brazil
Prior art keywords
mediated disorder
arthritis
inflammation
processes
pharmaceutical composition
Prior art date
Application number
BR9809147-6A
Other languages
Portuguese (pt)
Inventor
Ashok Anantanarayan
Michael Clare
Paul W Collins
Joyce Zuowu Crich
Rajesh Devraj
Daniel L Flynn
Lifeng Geng
Gunnar J Hanson
Francis J Koszyk
Shuyuan Liao
Richard A Partis
Shashidhar N Rao
Shaun Raj Selness
Michael S South
Michael A Stealey
Richard M Weier
Xiangdong Xu
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Publication of BR9809147A publication Critical patent/BR9809147A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"COMPOSTO PIRAZOL SUBSTITUìDO, COMPOSIçãO FARMACêUTICA, PROCESSOS PARA TRATAR UM DISTúRBIO MEDIADO POR TNF, UM DISTúRBIO MEDIADO POR QUINASE P38, INFLAMAçãO E ARTRITE, E, PARA PREPARAR PIRAZóIS". Uma classe de derivados de pirazol é descrita para uso no tratamento de distúrbios mediados por quinase p38. Os compostos de particular interesse são definidos pela fórmula (I), em que R^ 1^, R^ 2^, R^ 3^, e R^ 4^ são como descritos no relatório."REPLACED PIRAZOL COMPOUND, PHARMACEUTICAL COMPOSITION, PROCESSES TO TREAT A TNF-MEDIATED DISORDER, A KINASE P38-MEDIATED DISORDER, INFLAMMATION AND ARTHRITIS, AND, TO PREPARE PIRAZOLES". A class of pyrazole derivatives is described for use in the treatment of p38 kinase-mediated disorders. The compounds of particular interest are defined by formula (I), where R ^ 1 ^, R ^ 2 ^, R ^ 3 ^, and R ^ 4 ^ are as described in the report.

BR9809147-6A 1997-05-22 1998-05-22 Substituted pyrazole compound, pharmaceutical composition, processes for treating a tnf mediated disorder, a p38 kinase mediated disorder, inflammation and arthritis, and for preparing pyrazoles BR9809147A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4757097P 1997-05-22 1997-05-22
PCT/US1998/010436 WO1998052940A1 (en) 1997-05-22 1998-05-22 SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS

Publications (1)

Publication Number Publication Date
BR9809147A true BR9809147A (en) 2000-08-01

Family

ID=21949743

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9809147-6A BR9809147A (en) 1997-05-22 1998-05-22 Substituted pyrazole compound, pharmaceutical composition, processes for treating a tnf mediated disorder, a p38 kinase mediated disorder, inflammation and arthritis, and for preparing pyrazoles

Country Status (24)

Country Link
EP (1) EP1000055A1 (en)
JP (1) JP2002508754A (en)
KR (1) KR20010012854A (en)
CN (1) CN1264377A (en)
AP (1) AP1246A (en)
AU (1) AU754830C (en)
BG (1) BG64313B1 (en)
BR (1) BR9809147A (en)
CA (1) CA2291115A1 (en)
EA (1) EA003925B1 (en)
EE (1) EE9900527A (en)
GE (1) GEP20033053B (en)
HU (1) HUP0001880A3 (en)
ID (1) ID22982A (en)
IL (1) IL132991A (en)
IS (1) IS5257A (en)
NO (1) NO995695L (en)
NZ (1) NZ501112A (en)
OA (1) OA12981A (en)
PL (1) PL337020A1 (en)
SK (1) SK157899A3 (en)
TR (1) TR200000235T2 (en)
WO (1) WO1998052940A1 (en)
ZA (1) ZA984358B (en)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW289752B (en) * 1994-03-11 1996-11-01 Ciba Geigy Ag
US5559137A (en) * 1994-05-16 1996-09-24 Smithkline Beecham Corp. Compounds
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
CA2288787A1 (en) 1997-05-22 1998-11-26 G.D. Searle And Co. Pyrazole derivatives as p38 kinase inhibitors
US6979686B1 (en) 2001-12-07 2005-12-27 Pharmacia Corporation Substituted pyrazoles as p38 kinase inhibitors
JP2002504909A (en) 1997-06-13 2002-02-12 スミスクライン・ビーチャム・コーポレイション New substituted pyrazole and pyrazoline compounds
US7301021B2 (en) 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
WO2000019824A1 (en) 1998-10-07 2000-04-13 Smithkline Beecham Corporation Novel treatment for stroke management
DE69903976T2 (en) 1998-12-16 2003-07-24 Aventis Pharma Ltd HETEROARYL CYCLIC ACETALS
US6191147B1 (en) 1998-12-24 2001-02-20 Ppd Discovery, Inc. Pyrazole compounds and uses thereof
ES2244231T3 (en) * 1998-12-25 2005-12-01 Teikoku Hormone Mfg. Co., Ltd. DERIVATIVES OF AMINOPIRAZOL.
NZ514756A (en) 1999-03-26 2004-04-30 Euro Celtique S Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof
WO2000075131A1 (en) * 1999-06-03 2000-12-14 Teikoku Hormone Mfg. Co., Ltd. Substituted pyrazole compounds
US7122666B2 (en) 1999-07-21 2006-10-17 Sankyo Company, Limited Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses
AU6909600A (en) * 1999-08-13 2001-03-13 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
WO2001030154A2 (en) * 1999-10-25 2001-05-03 Basf Aktiengesellschaft Agrochemical compositions containing pyrazoles and use thereof as fungicidal plant protection agents
DE19952147A1 (en) 1999-10-29 2001-05-03 Boehringer Ingelheim Pharma New cyclopropanes, pharmaceutical compositions containing these compounds and process for their preparation
DE60015599T2 (en) 1999-11-23 2005-11-03 Smithkline Beecham Corp. 3,4-DIHYDRO- (1H) CHINAZOLIN-2-ON COMPOUNDS AS CSBP / p38 KINASE INHIBITORS
EP1309592B9 (en) 2000-08-14 2007-02-28 Ortho-McNeil Pharmaceutical, Inc. Substituted pyrazoles
EP1364949A4 (en) 2001-02-02 2005-11-23 Takeda Pharmaceutical Jnk inhibitor
GB0102687D0 (en) 2001-02-02 2001-03-21 Pharmacia & Upjohn Spa Oxazolyl-pyrazole derivatives active as kinase inhibitors,process for their preparation and pharmaceutical compositions comprising them
EP1382603B1 (en) 2001-04-26 2008-07-23 Eisai R&D Management Co., Ltd. Nitrogenous fused-ring compound having pyrazolyl group as substituent and medicinal composition thereof
ES2289116T3 (en) 2001-05-24 2008-02-01 Eli Lilly And Company NEW DERIVATIVES OF PIRROL AS PHARMACEUTICAL AGENTS.
US7057049B2 (en) 2001-09-25 2006-06-06 Pharmacia Corporation Process for making substituted pyrazoles
MXPA04002855A (en) 2001-09-25 2004-07-05 Pharmacia Corp Process for making substituted pyrazoles.
MXPA04011638A (en) * 2002-06-05 2005-03-07 Pharmacia Corp Pyrazole-derivatives as p38 kinase inhibitors.
EP1534282B1 (en) 2002-07-09 2006-12-27 Boehringer Ingelheim Pharma GmbH & Co.KG Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
GB0215844D0 (en) 2002-07-09 2002-08-14 Novartis Ag Organic compounds
GB0217786D0 (en) * 2002-07-31 2002-09-11 Glaxo Group Ltd Compounds
US6649638B1 (en) 2002-08-14 2003-11-18 Ppd Discovery, Inc. Prenylation inhibitors and methods of their synthesis and use
US7166619B2 (en) 2002-08-14 2007-01-23 Ppd Discovery , Inc. Prenylation inhibitors and methods of their synthesis and use
WO2004026302A1 (en) * 2002-09-19 2004-04-01 Eli Lilly And Company Methods of inhibiting tgf beta with substituted pyrazoles
GB0229618D0 (en) * 2002-12-19 2003-01-22 Cancer Rec Tech Ltd Pyrazole compounds
CA2515119A1 (en) 2003-02-07 2004-08-19 Daiichi Pharmaceutical Co., Ltd. Pyrazole derivative
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
JP4084836B2 (en) 2004-08-12 2008-04-30 ファイザー・インク Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors
PE20060777A1 (en) 2004-12-24 2006-10-06 Boehringer Ingelheim Int INDOLINONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES
WO2006070927A1 (en) 2004-12-28 2006-07-06 Aska Pharmaceutical Co., Ltd. Pyrimidinylisoxazol derivative
CA2643066A1 (en) * 2006-03-16 2007-09-20 Pfizer Products Inc. Pyrazole compounds
WO2008001930A1 (en) 2006-06-28 2008-01-03 Aska Pharmaceutical Co., Ltd. Pyridylisoxazole derivative
CN101478989A (en) 2006-06-28 2009-07-08 Aska制药株式会社 Treatment agent for inflammatory bowel disease
WO2008099615A1 (en) 2007-02-16 2008-08-21 Aska Pharmaceutical Co., Ltd. Pharmaceutical composition containing fine particle oil-based suspension
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
WO2009010455A2 (en) * 2007-07-13 2009-01-22 Addex Pharma S.A. Pyrazole derivatives as modulators of metabotropic glutamate receptors
AR069545A1 (en) 2007-11-16 2010-02-03 Boehringer Ingelheim Pharma DERIVATIVES OF ARIL AND HETEROARILCARBONILO OF RELATED BENZOMORPHANS AND RELATED STRUCTURES, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS, OBTAINING THEMSELVES, THEIR USE IN THE TREATMENT OF DISEASES MEDIATED BY THE INHIBITION OF THE HIDDEN AND DISEASE
CL2009000904A1 (en) 2008-04-21 2010-04-30 Shionogi & Co Compounds derived from cyclohexyl sulfonamides having antagonist activity at the npy y5 receptor, pharmaceutical composition and pharmaceutical formulation comprising them.
CA2724214A1 (en) 2008-05-13 2009-11-19 Boehringer Ingelheim International Gmbh Alicyclic carboxylic acid derivatives of benzomorphans and related scaffolds, medicaments containing such compounds and their use
ES2386408T3 (en) 2008-07-24 2012-08-20 Nerviano Medical Sciences S.R.L. 3,4-Diarylpyrazoles as protein kinase inhibitors
CA2735204C (en) * 2008-08-25 2017-06-20 Boehringer Ingelheim International Gmbh Aryl- and heteroarylcarbonyl derivatives of substituted nortropanes, medicaments containing such compounds and their use
WO2010045764A1 (en) * 2008-10-23 2010-04-29 Lonza Ltd Process for the synthesis of substituted pyrazoles
BRPI0921097B8 (en) * 2008-11-21 2021-05-25 Raqualia Pharma Inc compound or its pharmaceutically acceptable salt, intermediate of the compound, pharmaceutical composition and use of the compound
EP2438049B1 (en) 2009-06-02 2014-05-14 Boehringer Ingelheim International GmbH Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
WO2011011123A1 (en) 2009-06-11 2011-01-27 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 based on the 1,3 -oxazinan- 2 -one structure
WO2011023677A1 (en) * 2009-08-26 2011-03-03 Novartis Ag Tetra-substituted heteroaryl compounds and their use as mdm2 and/or mdm4 modulators
JO3002B1 (en) 2009-08-28 2016-09-05 Irm Llc Compounds and compositions as protein kinase inhibitors
EP2308866A1 (en) 2009-10-09 2011-04-13 Bayer CropScience AG Phenylpyri(mi)dinylpyrazoles and their use as fungicides
EP2516423A1 (en) 2009-12-21 2012-10-31 Bayer CropScience AG Thienylpyri (mi) dinylazole and their use for controlling phytopathogenic fungi
BR112012017705B1 (en) 2010-01-27 2020-03-24 Nerviano Medical Science S.R.L. 3,4-DIARYLPIRAZOL SULPHONAMID DERIVATIVES AS PROTEIN KINASE INHIBITORS
AR081810A1 (en) 2010-04-07 2012-10-24 Bayer Cropscience Ag BICYCLE PIRIDINYL PIRAZOLS
US8933072B2 (en) 2010-06-16 2015-01-13 Vitae Pharmaceuticals, Inc. Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use
WO2012016993A1 (en) 2010-08-03 2012-02-09 Nerviano Medical Sciences S.R.L. Derivatives of pyrazolophenyl-benzenesulfonamide compounds and use thereof as antitumor agents
PL3181133T3 (en) * 2010-12-20 2019-12-31 Pfizer Inc. Novel fused pyridine compounds as casein kinase inhibitors
AR086992A1 (en) 2011-06-20 2014-02-05 Bayer Ip Gmbh TIENILPIRI (MI) DINILPIRAZOLES
US8735585B2 (en) 2011-08-17 2014-05-27 Boehringer Ingelheim International Gmbh Indenopyridine derivatives
UA114410C2 (en) 2011-10-06 2017-06-12 Байєр Інтеллектуал Проперті Гмбх Heterocyclylpyri(mi)dinylpyrazole
ES2689110T3 (en) 2011-10-06 2018-11-08 Bayer Cropscience Ag Heterocyclylpiri (mi) dinylpyrazoles as fungicides
DE102011115525A1 (en) 2011-10-11 2013-04-11 Boehringer Ingelheim International Gmbh Two-part bottle packaging device for containing pharmaceutical tablets or capsules, has bottle body and bottle base, where bottle is closed with pressure lock or with pressure lock injected at bottle body or with separate rotary lock
AU2012335663B2 (en) 2011-11-11 2015-12-24 Array Biopharma Inc. Method of treating a proliferative disease
US9387208B2 (en) 2011-11-23 2016-07-12 Novartis Ag Pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate
JP6579623B2 (en) 2013-03-15 2019-09-25 ザ・スクリップス・リサーチ・インスティテュート Compounds and methods for inducing cartilage formation
WO2015088038A1 (en) * 2013-12-12 2015-06-18 住友化学株式会社 Aromatic compound and application for same
CN104829536B (en) * 2015-05-04 2017-12-29 陕西科技大学 A kind of Phenylpyrazole carboxylic acid compound and its synthetic method for having antitumor activity
JP6746614B2 (en) * 2015-05-27 2020-08-26 杏林製薬株式会社 Urea derivative or its pharmacologically acceptable salt
CN112480079B (en) * 2017-11-08 2022-03-11 北京嘉林药业股份有限公司 Compounds and their use for treating cancer
EP3886854A4 (en) 2018-11-30 2022-07-06 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
US11091447B2 (en) 2020-01-03 2021-08-17 Berg Llc UBE2K modulators and methods for their use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559137A (en) * 1994-05-16 1996-09-24 Smithkline Beecham Corp. Compounds
US5486534A (en) * 1994-07-21 1996-01-23 G. D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation

Also Published As

Publication number Publication date
AU7588398A (en) 1998-12-11
IL132991A (en) 2005-11-20
EA003925B1 (en) 2003-10-30
ZA984358B (en) 1999-05-24
PL337020A1 (en) 2000-07-31
OA12981A (en) 2006-10-13
IL132991A0 (en) 2001-03-19
EA199900953A1 (en) 2000-10-30
AU754830B2 (en) 2002-11-28
NO995695D0 (en) 1999-11-19
EE9900527A (en) 2000-06-15
AU754830C (en) 2004-02-12
JP2002508754A (en) 2002-03-19
EP1000055A1 (en) 2000-05-17
NZ501112A (en) 2002-10-25
CA2291115A1 (en) 1998-11-26
NO995695L (en) 2000-01-21
HUP0001880A3 (en) 2002-03-28
AP9901715A0 (en) 1999-12-31
BG64313B1 (en) 2004-09-30
AP1246A (en) 2004-02-07
HUP0001880A2 (en) 2001-03-28
BG103964A (en) 2000-08-31
ID22982A (en) 1999-12-23
WO1998052940A1 (en) 1998-11-26
TR200000235T2 (en) 2000-05-22
KR20010012854A (en) 2001-02-26
GEP20033053B (en) 2003-08-25
CN1264377A (en) 2000-08-23
SK157899A3 (en) 2000-08-14
IS5257A (en) 1999-11-19

Similar Documents

Publication Publication Date Title
BR9809147A (en) Substituted pyrazole compound, pharmaceutical composition, processes for treating a tnf mediated disorder, a p38 kinase mediated disorder, inflammation and arthritis, and for preparing pyrazoles
BR9915420A (en) Compound, pharmaceutical composition, methods of treating a disorder mediated by TNF and p38 kinase, inflammation and arthritis and the process of preparing pyrazoles
BR9808953A (en) Compound, process to treat a cyclooxygenase-2 mediated disorder in a patient, and pharmaceutical composition
BR9916282A (en) Compound, use of a compound and method of treatment
BR0317717A (en) Compound, pharmaceutical composition, use of a compound, method for treating a human suffering from a disease, and process for the preparation of a compound
BR9305907A (en) Use of substituted derivatives for the treatment of multiple sclerosis
BR9810592A (en) Compound, processes for preparing a compound, for treating or preventing diseases of the endocrine system and for the manufacture of a drug, pharmaceutical composition, and, use of a compound
BR9911482A (en) Compound, pharmaceutical composition, use of the compound, and, processes for the treatment or prophylaxis of inflammatory diseases, and for the preparation of a compound
BR0312464A (en) Tyrosine kinase inhibitors
DE3568272D1 (en) 4-vinylbenzoic-acid derivatives, their preparation and their use as therapeutical compositions and as ligands
GEP20043237B (en) Pyrazoline Derivatives, Method for Their Preparation and Compositions Containing Them for Treatment of Diseases Mediated by Cyclooxygenase-2
BR9915011A (en) Compounds, method for preparing them, pharmaceutical composition, methods of treating a human or animal individual suffering from a condition that is mediated by selective inhibition of cox-2 and suffering from an inflammatory disorder, and, use of a compound
AP9901435A0 (en) Bicycle heteroaromatic compounds as protein tyrosine kinase inhibitors.
BRPI0012352B8 (en) indazole compounds or pharmaceutically acceptable salt and pharmaceutical composition
BR9907886A (en) Compound, use of it, pharmaceutical composition, and, treatment process or prophylaxis of inflammatory diseases, for example asthma or copd.
BR9914696A (en) Compound, process for treating cyclooxygenase-2-mediated disorder in an individual, and pharmaceutical composition
AU6226494A (en) Spiroazacyclic derivatives as substance p antagonists
BRPI0314308B8 (en) opioid antagonists, their uses, and pharmaceutical composition
BR9714082A (en) Compound, use thereof, pharmaceutical composition, and, processes for treatment or prophylaxis of inflammatory diseases, and for the preparation of a compound.
BR0206435A (en) Compound, pharmaceutical composition, methods of treating angiogenesis in a patient, treating kdr and proliferative-related disorders in a mammal, use of a compound, and process for preparing compounds
DK0641328T3 (en) Bridged, azabicyclic derivatives as substance P antagonists
BR0212986A (en) Imizadol-4-carboxamide derivatives, preparation and use for obesity treatment
HU9303051D0 (en) Substituted quinuclidine derivatives
BR9811482A (en) 1- (n-phenylaminoalkyl) -piperazine derivatives substituted in position 2 of the phenolic ring
BR9507073A (en) Composed processes to prepare the same and to treat a disease in the central nervous system pharmaceutical composition and use of the compound

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DE ACORDO COM ART. 8O DA LPI.